Lenvatinib HCC Results Give Sorafenib Cause To REFLECT?

New comparative data released at ASCO reveal the scope of benefit for Eisai's lenvatinib over close competitor sorafenib in the first-line treatment of unresectable hepatocellular carcinoma. But the Eisai drug may face challenges in carving a position in this setting.

Liver infection

Lenvatinib mesylate hit both its primary and secondary endpoints in a large Phase III trial comparing it with sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (HCC), Eisai Co. Ltd.'s oral multi-kinase inhibitor in the process becoming the first systemic therapy to show statistical non-inferiority to its marketed rival in terms of median overall survival (OS).

Lenvatinib also showed "statistically significant and clinically meaningful improvements" against a range of secondary endpoints, including progression-free survival (PFS), time...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from R&D

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza